Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fry

Showing results (191-200 of 201) with videos related to

Pageof 21
Sort By:
Journal of Medicinal Chemistry|May 29, 1999
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.
Journal of Virology|April 24, 2009
Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantationPim L J van der Heiden, Renate de Boer, Dirk M van der Steen, et al.
Journal of the National Cancer Institute|April 20, 2001
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancerS M Lippman, J J Lee, D D Karp, et al.
The Mount Sinai Journal of Medicine, New York|November 21, 2008
Diversity in academic medicine no. 6 successful programs in minority faculty development: ingredients of successSandra P Daley, Ann-Gel Palermo, Marc Nivet, et al.
Journal of Medicinal Chemistry|July 18, 1997
Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitorsJ M Hamby, C J Connolly, M C Schroeder, et al.
Nature Communications|October 1, 2025
Long-persisting SARS-CoV-2 spike-specific CD4<sup>+</sup> T cells associated with mild disease and increased cytotoxicity post COVID-19Guihai Liu, Elie Antoun, Anastasia Fries, et al.
Journal of Medicinal Chemistry|February 17, 2006
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptorsSylvester R Klutchko, Hairong Zhou, R Thomas Winters, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Broad and strong memory CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patientsYanchun Peng, Alexander J Mentzer, Guihai Liu, et al.
Nature Immunology|December 2, 2021
An immunodominant NP<sub>105-113</sub>-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 diseaseYanchun Peng, Suet Ling Felce, Danning Dong, et al.
Pageof 21

Showing results (191-200 of 201) with videos related to

Sort By:
Pageof 21
Journal of Medicinal Chemistry|May 29, 1999
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.
Journal of Virology|April 24, 2009
Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantationPim L J van der Heiden, Renate de Boer, Dirk M van der Steen, et al.
Journal of the National Cancer Institute|April 20, 2001
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancerS M Lippman, J J Lee, D D Karp, et al.
The Mount Sinai Journal of Medicine, New York|November 21, 2008
Diversity in academic medicine no. 6 successful programs in minority faculty development: ingredients of successSandra P Daley, Ann-Gel Palermo, Marc Nivet, et al.
Journal of Medicinal Chemistry|July 18, 1997
Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitorsJ M Hamby, C J Connolly, M C Schroeder, et al.
Nature Communications|October 1, 2025
Long-persisting SARS-CoV-2 spike-specific CD4<sup>+</sup> T cells associated with mild disease and increased cytotoxicity post COVID-19Guihai Liu, Elie Antoun, Anastasia Fries, et al.
Journal of Medicinal Chemistry|February 17, 2006
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptorsSylvester R Klutchko, Hairong Zhou, R Thomas Winters, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Broad and strong memory CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patientsYanchun Peng, Alexander J Mentzer, Guihai Liu, et al.
Nature Immunology|December 2, 2021
An immunodominant NP<sub>105-113</sub>-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 diseaseYanchun Peng, Suet Ling Felce, Danning Dong, et al.
Pageof 21